Loading
An immune-stimulating antibody for myeloma that works only in combination, adding benefit to lenalidomide or pomalidomide.
Elotuzumab is a monoclonal antibody against SLAMF7 (CS1), a surface protein on both myeloma cells and natural killer cells. It marks myeloma cells for NK-mediated antibody-dependent cellular cytotoxicity and simultaneously activates the NK cells, but it has no single-agent activity and is always combined with an immunomodulatory drug and dexamethasone. ELOQUENT-2 (2015) showed median progression-free survival of 19.4 versus 14.9 months when added to lenalidomide-dexamethasone in patients after 1 to 3 prior therapies, leading to US approval in 2015. ELOQUENT-3 (2018) supported a second approval with pomalidomide-dexamethasone after at least two therapies. CD38 antibodies have largely displaced it, but it remains an option in daratumumab-refractory disease and is generally well tolerated. The key idea is an antibody that works only by recruiting the patient's own immune cells.
Binds SLAMF7 (CS1) on myeloma cells and NK cells, enhancing NK-mediated ADCC; no single-agent activity.
1.Elotuzumab binds its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies.
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA434. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2015 | Multiple myeloma after 1-3 prior therapies, with lenalidomide-dexamethasone |
| US | 2018 | With pomalidomide-dexamethasone after ≥2 therapies |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Elotuzumab" OR ABSTRACT:"Elotuzumab" OR TITLE:"Empliciti" OR ABSTRACT:"Empliciti") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Elotuzumab, not a curated reading list.
Shares Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other, Multiple myeloma.
Shares A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre, Bristol Myers Squibb, Multiple myeloma.
Shares Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto, A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re, A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other.
Shares Bristol Myers Squibb, Monoclonal antibodies, Multiple myeloma.
Shares Bristol Myers Squibb, Multiple myeloma.
Shares Bristol Myers Squibb, Multiple myeloma.